› 4aza

X-ray diffraction
2.16Å resolution

Improved eIF4E binding peptides by phage display guided design.

Released:
DOI: 10.2210/pdb4aza/pdb
PDB entry 4aza coloured by chain, front view.
PDB entry 4aza coloured by chain, side view.
PDB entry 4aza coloured by chain, top view.
Source organism: Homo sapiens
Primary publication:
Improved eIF4E binding peptides by phage display guided design: plasticity of interacting surfaces yield collective effects.
Zhou W, Quah ST, Verma CS, Liu Y, Lane DP, Brown CJ
PLoS One 7 e47235 (2012)
PMID: 23094039

Function and Biology Details

Biochemical function:
Biological process:
Cellular component:
Sequence domains:

Structure analysis Details

Assembly composition:
hetero dimer (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-139175 (preferred)
Entry contents:
2 distinct polypeptide molecules
Macromolecules (2 distinct):
Eukaryotic translation initiation factor 4E Chains: A, C
Molecule details ›
Chains: A, C
Length: 217 amino acids
Theoretical weight: 25.13 KDa
Source organism: Homo sapiens
Expression system: Escherichia coli BL21(DE3)
UniProt:
  • Canonical: P06730 (Residues: 1-217; Coverage: 100%)
Gene names: EIF4E, EIF4EL1, EIF4F
Sequence domains: Eukaryotic initiation factor 4E
Structure domains: RNA Cap, Translation Initiation Factor Eif4e
Eukaryotic translation initiation factor 4 gamma 1 Chains: B, D
Molecule details ›
Chains: B, D
Length: 14 amino acids
Theoretical weight: 1.57 KDa
Source organism: Homo sapiens
Expression system: Not provided
UniProt:
  • Canonical: Q04637 (Residues: 609-620; Coverage: 1%)
Gene names: EIF4F, EIF4G, EIF4G1, EIF4GI

Ligands and Environments

1 bound ligand:
Ligand MGO 2 x MGO
No modified residues

Experiments and Validation Details

Entry percentile scores
X-ray source: RIGAKU PROTEUM
Spacegroup: P21
Unit cell:
a: 60.662Å b: 38.168Å c: 121.758Å
α: 90° β: 90° γ: 90°
R-values:
R R work R free
0.235 0.233 0.279
Expression systems:
  • Escherichia coli BL21(DE3)
  • Not provided

Quick links

Citations

2 review citations

Drugging the p53 pathway: understanding the route to clinical efficacy.
Khoo et al. (2014)
1 more

5 mentions without citation

Bioinformatics and Biosimulations as Toolbox for Peptides and Peptidomimetics Design: Where Are We?
D'Annessa et al. (2020)
4 more